Page last updated: 2024-12-04

pantoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

pantoic acid: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID439251
CHEMBL ID1794671
CHEBI ID18697
SCHEMBL ID213982
MeSH IDM0065766

Synonyms (26)

Synonym
unii-0j1tl6g6j9
1112-33-0
butanoic acid, 2,4-dihydroxy-3,3-dimethyl-, (r)-
0j1tl6g6j9 ,
C00522
pantoic acid
(r)-pantoic acid
CHEBI:18697 ,
(2r)-2,4-dihydroxy-3,3-dimethylbutanoic acid
AKOS006378584
CHEMBL1794671
(r)-2,4-dihydroxy-3,3-dimethylbutanoic acid
d-pantoic acid
(-)-pantoic acid
dexpanthenol impurity b [ep impurity]
pantoic acid, (r)-
butanoic acid, 2,4-dihydroxy-3,3-dimethyl-, (2r)-
SCHEMBL213982
dexpanthenol impurity b
OTOIIPJYVQJATP-BYPYZUCNSA-N
Q23054703
DTXSID101016980
d-(+)-pantoicacid
(r)-2,4-dihydroxy-3,3-dimethylbutanoicacid
EN300-176271
Z1205493806
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pantoic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
pantothenate and coenzyme A biosynthesis022

Bioassays (5)

Assay IDTitleYearJournalArticle
AID603206Binding affinity to Mycobacterium tuberculosis pantothenate synthetase assessed as beta-sheet structural changes by crystal structure analysis (Rvb = 21.3 %%)2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition.
AID603204Binding affinity to Mycobacterium tuberculosis pantothenate synthetase assessed as beta-sheet structural changes by circular dichroism spectra analysis (Rvb = 8.19 %%)2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition.
AID603208Binding affinity to Mycobacterium tuberculosis pantothenate synthetase by tryptophan fluorescence quenching assay2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition.
AID603203Binding affinity to Mycobacterium tuberculosis pantothenate synthetase assessed as alpha-helix structural changes by circular dichroism spectra analysis (Rvb = 47.93 %%)2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition.
AID603205Binding affinity to Mycobacterium tuberculosis pantothenate synthetase assessed as alpha-helix structural changes by crystal structure analysis (Rvb = 41.3 %%)2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (43.33)18.7374
1990's4 (13.33)18.2507
2000's5 (16.67)29.6817
2010's5 (16.67)24.3611
2020's3 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (96.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]